Related Experiment Video

Updated: May 10, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Molecular determinants of resistance to antiandrogen therapy

Charlie D Chen1, Derek S Welsbie, Chris Tran

  • 1Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA.

Nature Medicine
|January 2, 2004
PubMed

Insights

Increased androgen receptor (AR) levels drive prostate cancer resistance to antiandrogen therapy by amplifying signaling and altering drug response. This finding is crucial for developing more effective antiandrogen treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer treatment often involves antiandrogen therapy.
  • Development of resistance to antiandrogens is a major clinical challenge.
  • The molecular mechanisms underlying antiandrogen resistance are not fully understood.

Purpose of the Study:

  • To investigate the molecular changes associated with the development of resistance to antiandrogen therapy in prostate cancer.
  • To determine the role of androgen receptor (AR) in conferring resistance.
  • To elucidate the mechanism by which increased AR levels lead to treatment failure.

Main Methods:

  • Utilized microarray-based profiling of isogenic prostate cancer xenograft models.
  • Assessed changes in gene expression, specifically androgen receptor mRNA and protein levels.
  • Investigated the functional consequences of altered AR levels on prostate cancer cell growth and response to antiandrogens.

Main Results:

  • A modest increase in androgen receptor (AR) mRNA was the sole consistent molecular alteration linked to antiandrogen resistance.
  • Elevated AR levels were necessary and sufficient to transition prostate cancer from hormone-sensitive to hormone-refractory.
  • AR antagonists exhibited agonistic activity in cells with high AR, linked to altered coactivator/corepressor recruitment.
  • Increased AR amplifies signaling from residual ligands and modifies antagonist responses.

Conclusions:

  • Elevated androgen receptor (AR) levels are a key driver of resistance to antiandrogen therapy in prostate cancer.
  • The mechanism involves enhanced signaling and altered drug response due to increased AR.
  • These findings offer critical insights for the design of novel antiandrogen therapies to overcome resistance.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...